Integrin scintimammography using a dedicated breast imaging, solid‐state γ‐camera and <sup>99m</sup>Tc‐labelled NC100692

Bach‐Gansmo, Tore; Bogsrud, Trond Velde; Skretting, Arne

doi:10.1111/j.1475-097x.2008.00801.x

“…One particularly attractive example is the work reported by Bach-Gansmo et al, who demonstrated how a novel probe coupled with new imaging technologies can yield exciting results (15). In this work, a technetium-labeled peptide that has high affinity for the a v b 3 -integrin was used in a breast cancer imaging study that applied both conventional scintimammography and a dedicated breast imaging system (16). The study showed that invasive ductal carcinomas ranging from 6 to 20 mm were well visualized.…”

Section: Organ-and Disease-specific Camerasmentioning

confidence: 99%

A Bridge Not Too Far: Linking Disciplines Through Molecular Imaging Probes

Valliant

¹

2016

J. Nucl. Med. Technol.

View full text Add to dashboard Cite

CE credit: For CE credit, you can access the test for this article, as well as additional JNMT CE tests, online at https://www.snmmilearningcenter.org. Complete the test online no later than September 2016. Your online test will be scored immediately. You may make 3 attempts to pass the test and must answer 80% of the questions correctly to receive 1.0 CEH (Continuing Education Hour) credit. SNMMI members will have their CEH credit added to their VOICE transcript automatically; nonmembers will be able to print out a CE certificate upon successfully completing the test. The online test is free to SNMMI members; nonmembers must pay $15.00 by credit card when logging onto the website to take the test.The field of nuclear medicine will rely increasingly on the discovery, proper evaluation, and clinical use of molecular imaging probes and on collaborations. Collaborations will include new initiatives among experts already involved in the field and with researchers, technologists, and clinicians from different areas of science and medicine. This article serves to highlight some of the opportunities in which molecular imaging and nuclear medicine in conjunction with probe development, new imaging technologies, and multidisciplinary collaborations can have a significant impact on health care and basic science from the perspective of a person involved in probe development. The article emphasizes breast cancer, but the concepts are readily applied to other areas of medicine and medical research. Nucl ear medicine is a unique field in that it relies on habitual collaboration between groups possessing disparate expertise. Nuclear medicine physicians work collaboratively on a daily basis with imaging physicists and nuclear medicine technologists who directly and indirectly rely on partnerships with biologists, chemists, engineers, and medical research teams to develop, validate, and produce radiopharmaceuticals. The future of nuclear medicine involves exploiting the full potential of molecular imaging and targeted radiotherapy and will require building on the existing culture of collaboration. To be truly successful, nuclear medicine will need to form bridges to groups outside the present sphere of collaboration-the underlying theme of this article.Society is facing challenging times that will shape the future of probe development. There has been a significant downturn in the world's economy that is affecting economic decisions made by consumers and governments, particularly with respect to health care. The world is in the midst of a protracted and ongoing isotope shortage, both an acute shortage associated with the shutdown of the reactor at Chalk River, limiting the supply of 99 Mo and 99m Tc, and a chronic underfunding of cyclotron laboratories. Economic pressures are affecting the way decisions are made about which new diagnostic technologies will ultimately be funded. This effect is true in public, private, and hybrid-model health-care systems, in which groups developing new probes must be conscious about both the healt...

show abstract

“…Fig. 11 shows the structure of NC100692 (maraciclatide), the RGD peptide that has been labeled with technetium for the study in breast cancer [67]. Fig.…”

Section: Spect Imaging Of Angiogenesismentioning

confidence: 99%

Radiotracers for SPECT imaging: current scenario and future prospects

Adak¹,

Bhalla

²

,

Raj

³

et al. 2012

Ract

View full text Add to dashboard Cite

Summary. Single photon emission computed tomography (SPECT) has been the cornerstone of nuclear medicine and today it is widely used to detect molecular changes in cardiovascular, neurological and oncological diseases. While SPECT has been available since the 1980s, advances in instrumentation hardware, software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper.The biggest change in the last decade has been the fusion of CT with SPECT, which has improved attenuation correction and image quality. Advances in collimator design, replacement of sodium iodide crystals in the detectors with cadmium zinc telluride (CZT) detectors as well as advances in software and reconstruction algorithms have all helped to retain SPECT as a much needed and used technology.Today, a wide spectrum of radiotracers is available for use in cardiovascular, neurology and oncology applications. The development of several radiotracers for neurological disorders is briefly described in this review, including [123 I]FP-CIT (DaTSCAN™) available for Parkinson's disease. In cardiology, while technetium-99m labeled tetrofosmin and technetium-99m labeled sestamibi have been well known for myocardial perfusion imaging, we describe a recently completed multicenter clinical study on the use of [ 123 I]mIBG (AdreView™) for imaging in chronic heart failure patients. For oncology, while bone scanning has been prevalent, newer radiotracers that target cancer mechanisms are being developed. Technetium-99m labeled RGD peptides have been reported in the literature that can be used for imaging angiogenesis, while technetium-99m labeled duramycin has been used to image apoptosis.While PET/CT is considered to be the more advanced technology particularly for oncology applications, SPECT continues to be the modality of choice and the workhorse in many hospitals and nuclear medicine centers. The cost of SPECT instruments also makes them more attractive in developing countries where the cost of a scan is still prohibitive for many patients.

show abstract

“…It has been shown in a previous study in females with histologically proven breast cancer that the detection of malignant breast tumors is feasible and efficient by scintigraphic imaging with 99m Tc-RGD peptide [67,68]. Fig.…”

Section: Spect Imaging Of Angiogenesismentioning

confidence: 99%

Radiotracers for SPECT imaging: current scenario and future prospects

Adak¹,

Bhalla²,

Raj³

et al. 2011

View full text Add to dashboard Cite

Summary. Single photon emission computed tomography (SPECT) has been the cornerstone of nuclear medicine and today it is widely used to detect molecular changes in cardiovascular, neurological and oncological diseases. While SPECT has been available since the 1980s, advances in instrumentation hardware, software and the availability of new radiotracers that are creating a revival in SPECT imaging are reviewed in this paper.The biggest change in the last decade has been the fusion of CT with SPECT, which has improved attenuation correction and image quality. Advances in collimator design, replacement of sodium iodide crystals in the detectors with cadmium zinc telluride (CZT) detectors as well as advances in software and reconstruction algorithms have all helped to retain SPECT as a much needed and used technology.Today, a wide spectrum of radiotracers is available for use in cardiovascular, neurology and oncology applications. The development of several radiotracers for neurological disorders is briefly described in this review, including [123 I]FP-CIT (DaTSCAN™) available for Parkinson's disease. In cardiology, while technetium-99m labeled tetrofosmin and technetium-99m labeled sestamibi have been well known for myocardial perfusion imaging, we describe a recently completed multicenter clinical study on the use of [ 123 I]mIBG (AdreView™) for imaging in chronic heart failure patients. For oncology, while bone scanning has been prevalent, newer radiotracers that target cancer mechanisms are being developed. Technetium-99m labeled RGD peptides have been reported in the literature that can be used for imaging angiogenesis, while technetium-99m labeled duramycin has been used to image apoptosis.While PET/CT is considered to be the more advanced technology particularly for oncology applications, SPECT continues to be the modality of choice and the workhorse in many hospitals and nuclear medicine centers. The cost of SPECT instruments also makes them more attractive in developing countries where the cost of a scan is still prohibitive for many patients.

show abstract

Integrin scintimammography using a dedicated breast imaging, solid‐state γ‐camera and ^99mTc‐labelled NC100692

Abstract: The combined use of NC100629 and a dedicated gamma-camera for breast imaging was highly effective in diagnosing breast cancer.

Cited by 42 publications

References 9 publications

A Bridge Not Too Far: Linking Disciplines Through Molecular Imaging Probes

A Bridge Not Too Far: Linking Disciplines Through Molecular Imaging Probes

Radiotracers for SPECT imaging: current scenario and future prospects

Radiotracers for SPECT imaging: current scenario and future prospects

Contact Info

Product

Resources

About

Integrin scintimammography using a dedicated breast imaging, solid‐state γ‐camera and 99mTc‐labelled NC100692

Abstract: The combined use of NC100629 and a dedicated gamma-camera for breast imaging was highly effective in diagnosing breast cancer.

Cited by 42 publications

References 9 publications

A Bridge Not Too Far: Linking Disciplines Through Molecular Imaging Probes

A Bridge Not Too Far: Linking Disciplines Through Molecular Imaging Probes

Radiotracers for SPECT imaging: current scenario and future prospects

Radiotracers for SPECT imaging: current scenario and future prospects

Contact Info

Product

Resources

About

Integrin scintimammography using a dedicated breast imaging, solid‐state γ‐camera and ^99mTc‐labelled NC100692